Regen BioPharma Inc financial data

Symbol
RGBP, RGBPP on OTC
Location
La Mesa, CA
Fiscal year end
30 September
Latest financial report
10-Q - Q3 2025 - 11 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.8 % +7.68%
Debt-to-equity -103 % +0.75%
Return On Equity 13.5 %
Return On Assets -538 % -53.4%
Operating Margin -309 % +34.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.6M shares +600%
Common Stock, Shares, Outstanding 31.6M shares +622%
Entity Public Float 1.05M USD -84%
Common Stock, Value, Issued 3.16K USD +619%
Weighted Average Number of Shares Outstanding, Basic 23.8M shares +464%
Weighted Average Number of Shares Outstanding, Diluted 23.8M shares +464%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 127K USD -17.8%
Revenue from Contract with Customer, Excluding Assessed Tax 237K USD 0%
Research and Development Expense 154K USD -27.6%
General and Administrative Expense 78K USD +67.3%
Costs and Expenses 655K USD -29.1%
Operating Income (Loss) -301K USD +23%
Nonoperating Income (Expense) -227K USD -111%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -973K USD -28.6%
Net Income (Loss) Attributable to Parent -702K USD -5.98%
Earnings Per Share, Basic 0 USD/shares +66.7%
Earnings Per Share, Diluted 0 USD/shares +66.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 135 USD
Accounts Receivable, after Allowance for Credit Loss, Current 177K USD +164%
Assets, Current 179K USD +17.5%
Assets 197K USD +15.7%
Accounts Payable, Current 30.5K USD +3.61%
Accrued Liabilities, Current 1.77M USD
Liabilities, Current 6.01M USD +12.9%
Liabilities 6.01M USD +12.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -205K USD
Retained Earnings (Accumulated Deficit) -21.1M USD -3.77%
Stockholders' Equity Attributable to Parent -5.82M USD -12.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -5.18M USD -4.99%
Liabilities and Equity 197K USD +15.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -66.4K USD +59.1%
Net Cash Provided by (Used in) Financing Activities 65.8K USD -60.3%
Common Stock, Shares Authorized 5.8B shares +1060%
Common Stock, Shares, Issued 31.6M shares +622%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -581 USD -117%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.8K USD +8838%
Deferred Tax Assets, Valuation Allowance 4.29M USD +3.38%
Deferred Tax Assets, Gross 4.29M USD +3.38%
Deferred Tax Assets, Operating Loss Carryforwards 4.29M USD +3.38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 800M shares 0%
Additional Paid in Capital 15.5M USD +7.25%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 64K USD -29.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%